Contents

PHARMACOECONOMIC FEASIBILITY OF APPLICATION OF LEVOFLOXACIN (TAVANIC) IN AMBULATORY TREATMENT OF PATIENTS WITH COMMUNITYACQUIRED PNEUMONIA 
Yu.I. Feshchenko, O.Ya. Dzyublik, G.B. Capitan 
The necessity of pharmacoeconomic studies for optimization of antibacterial therapy of patients with community-acquired pneumonia (CAP) has been substantiated. The example of comparative economical evaluation of levofloxacin (Tavanic) and cefuroxim axetil (CA) in ambulatory treatment of patients with CAP has been given. The results of economical analysis demonstrated a significantly lower general cost of therapy using Tavanic in comparison with CA. 
Key words: pharmacoeconomical studies, community-acquired pneumonia, levofloxacin, TAVANIC.
Yu.I. Feshchenko, O.Ya. Dzyublik, G.B. Capitan Pharmacoeconomic feasibility of application of levofloxacin (tavanic) in ambulatory treatment of patients with communityacquired pneumonia // Ukr. J. Chemotherapy.- 2002.- N 2.- P. 3 - 8

AZITHROMYCIN IN TREATMENT OF RESPIRATORY TRACT INFECTIONS 
O.Ya. Dzyublik 
The data about azithromycin efficacy in treatment of respiratory tract infections and prevalence of antibiotic resistant strains of common respiratory pathogens throughout the world have been adduced. It was noted that the efficacy of azithromycin remained on a high level during 20 years of its clinical use. Nowadays this antibiotic is a medicine of choice in treatment of lower respiratory tract infections and a second line medicine in treatment of upper respiratory tract infections. 
Key words: azithromycin, pharmacokinetics, respiratory tract infections, antibiotic resisitance. 
O.Ya. Dzyublik Azithromycin in treatment of respiratory tract infections // Ukr. J. Chemotherapy.- 2002.- N 2.- P. 9 - 16 

MOXIFLOXACIN - THE NEW FLUOROQUINOLON WITH BROAD SPECTRUM OF ACTIVITY THE LITERATURE REVIEW 
L.S. Stratchounski, V.A. Kretchikov 
Moxifloxacin - new broad spectrum 8-methoxiquinolon with high activity against Gram(+) and Gram(-) microorganisms as well as against anaerobes and intracellular pathogens. It is also active against microorganisms that are resistant to other classes of antimicrobials, including penicillinand macrolide-resistant pneumococci and b-lactamase-producing Haemophilus influenzae. In the controlled clinical trials the high clinical efficacy and safety of moxifloxacin have been demonstrated for community-acquired pneumonia, exacerbation of chronic bronchitis, acute sinusitis, skin and soft tissue infections, pelvic inflammatory diseases. In the article the literature review of microbiological studies and clinical trials on moxifloxacin is presented. 
Key words: moxifloxacin, fluoroquinolones, respiratory tract infections. 
L.S. Stratchounski, V.A. Kretchikov Moxifloxacin - the new fluoroquinolon with broad spectrum of activity the literature review // Ukr. J. Chemotherapy.- 2002.- N 2.- P. 17 - 31

ANTIHOMOTOXIC THERAPY AS A LINK BETWEEN PHARMACOLOGICAL AND HOMEOPATHIC METHODS OF TREATMENT 
L.B. Yaroshchuk 
The basic principles of modern trend of biological medicines are described. A disease is considered as a biologically expedient process of organism's defense against homotoxins. The characteristics of complex antihomotoxic medicines and the result of their application in different diseases are presented. Antihomotoxic medicines possess immunomodulative properties, enhancing organism detoxicative functions. The application of these drugs is not associated with any allergies, side effects or toxic effects. Thus, these medicines can be administered in pregnant and lactating women, newborns and elderly patients. 
Key words: homotoxicology, biological medicine, antihomotoxic drugs, additional immune response. 
L.B. Yaroshchuk Antihomotoxic therapy as a link between pharmacological and homeopathic methods of treatment // Ukr. J. Chemotherapy.- 2002.- N 2.- P. 32 - 38

THE EFFICACY OF CEFTRIAXON AND TOBRAMYCIN IN TREATMENT OF PATIENTS WITH HOSPITAL-ACQUIRED PNEUMONIA, ADMITTED TO INTENSIVE CARE UNIT BECAUSE OF MYOCARDIAL INFARCTION 
O.O. Mukhin, K.M. Amosova, G.V. Myasnikov, M.O. Moskvichev, V.G. Slabchenko, R.E. Sukhin, N.V. Melnichenko, A.B. Sablin, O.O. Fastova 
The results of conducted study indicated that application of ceftriaxone in combination with tobramycin (ceftriaxon 2 g IV and tobramycin 240 mg once daily for 7-10 days) was highly effective in patients with hospital-acquired pneumonia, admitted to intensive care unit because of myocardial infarction. The treatment success (clinical improvement) was achieved in 88,3 % of cases. 
Key words: hospital-acquired pneumonia, antibacterial therapy, ceftriaxon, tobramycin, myocardial infarction. 
The efficacy of ceftriaxon and tobramycin in treatment of patients with hospital-acquired pneumonia, admitted to intensive care unit because of myocardial infarction Mukhin O.O., Amosova K.M., Myasnikov G.V. et al. // Ukr. J. Chemotherapy.- 2002.- N 2.- P. 39 - 42

THE INFLUENCE OF INTENSIVE ANTIMYCOBACTERIAL POLYCHEMOTHERAPY ON RENAL FUNCTION IN PATIENTS WITH NEWLY DIAGNOSED DESTRUCTIVE PULMONARY TUBERCULOSIS 
V.P. Shapovalov, B.I. Kvasnitsky, V.M. Melnyk 
The daily administration of antimycobacterial drugs in patients with newly diagnosed destructive pulmonary tuberculosis essentially influences an acidbase equilibrium and results in damage of sodium- dependent mechanisms of urine acidification. We recommend an intermittent regimens of a polychemotherapy with application of nephroprotective medications. 
Key words: pulmonary tuberculosis, antimycobacterial polychemotherapy, renal function.
V.P. Shapovalov, B.I. Kvasnitsky, V.M. Melnyk The influence of intensive antimycobacterial polychemotherapy on renal function in patients with newly diagnosed destructive pulmonary tuberculosis // Ukr. J. Chemotherapy.- 2002.- N 2.- P. 43 - 48

TREATMENT OF GLOMERULONEPHRITIS WITH NEPHROTIC SYNDROM USING CYCLOPHOSPHAMIDE IN PULSE DOSES 
L.A. Pyrih, I.O. Dudar 
The effects of treatment using pulse doses of cyclophosphamide (1000-1500 mg (20-25 mg/kg) intravenously monthly for 3-12 months) were analyzed. 29 patients with glomerulonephritis and nephrotic syndrome (27 diagnoses made by morphology) were examined. The expediency of application of this treatment has been demonstrated in cases of moderate doses prednisolone and cyclophosphamid therapy failure, as well as in presence of complications, relapsing course of a glomerulonephritis or concomitant diabetes mellitus, obesity, hypertension, or in senior age patients and in those cases, when prednisolone had been contraindicated. 
Key words: glomerulonephritis, treatment, nephrotic syndrome, cyclophosphamide, pulse doses, efficacy. 
L.A. Pyrih, I.O. Dudar Ttreatment of glomerulonephritis with nephrotic syndrom using cyclophosphamide in pulse doses // Ukr. J. Chemotherapy.- 2002.- N2.- P. 49 - 52

COMPLEX ULTRASONIC EXAMINATION FOR EVALUATION OF EFFECTIVENESS OF NEOADJUVANT THERAPY IN PATIENTS WITH BREAST CANCER 
V.E. Medvedev, T.S. Golovko, T.O. Tarasova 
The purpose of this innovation is the increase of effectiveness of monitoring of breast cancer neoadjuvant therapy utilizing complex ultrasound examination, including traditional ultrasound, energetic and color Doppler ultrasonography of pathological formations of breast and lymph nodes. We examined 46 women with morphologically confirmed breast cancer using a proposed method. The results of ultrasound and morphological examinations (volume of vital tumor tissue) were compared. The validity of complex ultrasound examination for valuation of efficiency of breast cancer neoadjuvant therapy was proved. 
Key words: breast cancer, complex ultrasound examination, color and energetic Doppler ultrasonography, volume of vital tumor tissue. 
V.E. Medvedev, T.S. Golovko, T.O. Tarasova Complex ultrasonic examination for evaluation of effectiveness of neoadjuvant therapy in patients with breast cancer // Ukr. J. Chemotherapy.- 2002.- N 2.- P. 53 - 55

BORDERLINE OVARIAN TUMORS 
O.V. Shlyahova, L.I. Vorobyeva, V.S. Svintsitskiy 
Borderline ovarian tumors comprise a separate group of neoplasms with potentially low grade of malignancy. The data of morphologic heterogeneity of this group of tumors have been presented. The tactical approach to the treatment of patients with borderline ovarian tumors has been outlined. The author supported the modern concept of infeasibility of neoadjuvant chemotherapy. This therapy could only be approved in III-IV stages of disease. That's why it is very important to define stages of borderline ovarian tumors. 
Key words: brderline ovarian tumors, epithelium proliferation, adjuvant chemoterapy. 
O.V. Shlyahova, L.I. Vorobyeva, V.S. Svintsitskiy Borderline ovarian tumors // Ukr. J. Chemotherapy.- 2002.- N 2.- P. 56 - 59  

EFFICIENCY OF COMPLEX APPLICATION OF ANTITUMOR VACCINE AND BLASTOLEN AS IMMUNOMODULATOR 
G.P. Potebnia, G.S. Lisovenko, V.S. Mosienko, V.G. Lisovenko 
We have studied the effectiveness of complex application of immunomodulator blastolen, derived from Lactobacillus Delbrueckii and antitumor vaccine, prepared from syngenic tumor cells (AV). AV was obtained using the products B. subtilis AB-56 synthesis. The expediency of complex use of blastolen and AV have been confirmed on the model of the solid form of a sarcoma-37 of BALB/c mice and the melanoma B-16 in C57Bl mice. Thus the essential advantage was observed when blastolen was injected 3 hours prior to AV. 
Key words: antitumor vaccine, immunomodulator, blastolen, B. subtilis AB-56. 
Efficiency of complex application of antitumor vaccine and blastolen as immunomodulator  Potebnia G.P., Lisovenko G.S., Mosienko V.S. et al. // Ukr. J. Chemotherapy.- 2002.- N 2.- P. 60 - 64 

ACUTE DISSEMINATED CANDIDOSIS 
Yu.I. Feshchenko, O.O. Mukhin, M.I. Gumenuk, N.M. Nedlinskaya, V. Ja. Klyagin, L.V. Chechel 
The modern data concerning diagnosing and treatment of acute disseminated candidosis have been presented. The place and role of fluconazol in the arsenal modern medicines for treatment of patients with this disease have been determined. 
Key words: acute disseminated candidosis, candidemia, candiduria, Candida spp., fluconazol.
Acute disseminated candidosis Feshchenko Yu.I., Mukhin O.O., Gumenuk M.I. et al. // Ukr. J. Chemotherapy.- 2002.- N 2.- P. 65

Contents